About Caring4Cancer

 
Caring4Cancer's mission is to provide a complete source of knowledge and support for people with cancer, empowering them with the expertise, strength and hope they need to live their lives to the fullest. Caring4Cancer combines a virtual encyclopedia of cancer information with a collection of powerful tools that help patients take an active role in managing their disease. Our world-renowned Oncology Advisory Board reviews our content for accuracy and timeliness.

At Caring4Cancer, you can:

  • Shape the content to match your specific cancer type, diagnosis, and phase of treatment or recovery
  • Interact with other patients and experts through our message boards
  • Keep track of your symptoms, treatments, and appointments with a secure Patient Health Record and Symptom Tracker
  • View online videos right in your doctor’s office or in the comfort of your own home
  • Sign up for e-newsletters tailored to your interests and needs.
  • Create your own personal web page where you can keep a personal journal, exchange messages of encouragement, share pictures, and more.

Hundreds of oncology practices are now prescribing Caring4Cancer’s educational and interactive tools to their patients, just as they prescribe medication or therapy.However, the content at Caring4Cancer is not intended to be a substitute for professional medical advice, diagnosis, or treatment. For information on how to contact us, please click here.

Latest Cancer News
Test Available for Pre-surgical Evaluation of Ovarian Mass

March 11, 2010 — For women who require surgery for an ovarian mass, the OVA1™ test may help identify the most appropriate type of surgeon. The test assesses the likelihood that cancer is present; when cancer is likely, surgery may best be performed by a gynecologic oncologist.

Oncotype DX® Predicts Recurrence Risk in Node-negative and Node-positive Breast Cancer Treated with Tamoxifen or Anastrozole

March 10, 2010 — Researchers affiliated with the TransATAC Study have reported that the Oncotype DX® test predicts the risk of distant cancer recurrence in postmenopausal women with early, hormone receptor-positive breast cancer with both node-negative and node-positive disease treated with tamoxifen (Nolvadex®) or anastrozole (Arimidex®). These results were published early online in the Journal of Clinical Oncology on March 8, 2010.

Recent Results of High-dose Proleukin® for Metastatic Renal Cell Carcinoma Reported

March 10, 2010 — Researchers involved in a U.S. multicenter trial (Cytokine Working Group) have reported that high-dose Proleukin® (aldesleukin, interleukin-2, IL-2) results in a higher response rate in patients with metastatic renal cell carcinoma (MRCC) than historically reported. The details of this study were presented at the 2010 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, March 5-7, in San Francisco.

Select news items provided by Reuters Health